Sutimlimab
Pre-clinicalRecruiting 0 watching 0 views this week💤 Quiet
20
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Cold Agglutinin Disease (CAD)
Conditions
Cold Agglutinin Disease (CAD), Cold Agglutinin Syndrome (CAS)
Trial Timeline
Dec 12, 2019 → Nov 2, 2028
NCT ID
NCT05791708About Sutimlimab
Sutimlimab is a pre-clinical stage product being developed by Recordati for Cold Agglutinin Disease (CAD). The current trial status is recruiting. This product is registered under clinical trial identifier NCT05791708. Target conditions include Cold Agglutinin Disease (CAD), Cold Agglutinin Syndrome (CAS).
Hype Score Breakdown
Clinical
5
Activity
2
Company
7
Novelty
2
Community
1
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05791708 | Pre-clinical | Recruiting |
Competing Products
20 competing products in Cold Agglutinin Disease (CAD)